STRIDE-II Treatment Targets for IBD
STRIDE-II (2021) establishes a tiered treat-to-target framework with short-term targets of symptomatic relief and biomarker normalization, intermediate targets of clinical remission, and long-term targets of endoscopic healing, quality of life restoration, and absence of disability 1.
Treatment Target Timeline
Short-Term Targets (Weeks to Months)
- Clinical response with symptomatic relief
- Normalization of inflammatory biomarkers:
Intermediate Targets (3-6 Months)
- Clinical remission (absence of rectal bleeding and normalization of stool frequency)
- Sustained biochemical normalization
- Real-world data shows combined targets (clinical remission plus CRP and FC normalization) achieved by 54% of Crohn's disease patients and 43% of ulcerative colitis patients by 6 months 2
Long-Term Targets (6-12 Months)
- Endoscopic healing (mucosal healing)
- Restoration of quality of life
- Absence of disability
- Normal growth in children (pediatric-specific)
Deeper Remission Measures (Not Formal Targets)
STRIDE-II designates these as adjunctive measures to assess remission depth rather than mandatory treatment targets:
- Histological healing in ulcerative colitis: Should be assessed as a measure of deeper healing but not required as a formal target 1
- Transmural healing in Crohn's disease: Similarly assessed but not mandated 1
However, emerging evidence suggests these deeper targets may predict better long-term outcomes 3, 4.
Critical Implementation Considerations
The Symptom-Inflammation Discordance Problem
Only 12% of patients in corticosteroid-free symptomatic remission on advanced therapy have moderate-to-severe endoscopic inflammation 5. This means most patients achieving symptomatic control also achieve endoscopic improvement, but the minority with persistent inflammation despite symptom control represents a critical treatment gap.
Patient Preference Reality
39% of patients decline treatment intensification because they prefer staying on current therapy, while only 11% prefer switching 5. This creates tension between the treat-to-target framework and patient autonomy—you must discuss incremental benefits of achieving deeper remission versus risks of treatment escalation with each patient.
Disease-Specific Challenges
Ulcerative Colitis:
- Higher relapse rates after achieving remission (67% vs 43% in Crohn's disease) 2
- Comprehensive disease control now includes patient-reported symptoms beyond traditional Mayo score: bowel urgency, abdominal pain, extraintestinal manifestations, fatigue, and sleep disturbance 3
Crohn's Disease:
- More consistent maintenance of remission once achieved
- Cross-sectional imaging for transmural assessment adds complexity
Monitoring Algorithm
- Weeks 0-12: Assess clinical symptoms and CRP every 4-8 weeks
- Weeks 12-24: Add fecal calprotectin monitoring; escalate therapy if targets not met
- Months 6-12: Perform endoscopy to assess mucosal healing
- Ongoing: Monitor quality of life, disability status, and growth (pediatrics) at each visit
Common Pitfalls
- Treating symptoms alone: Up to half of UC patients remain inadequately controlled by STRIDE-II criteria despite symptom improvement due to persistent inflammation, steroid dependence, or impaired quality of life 6
- Premature treatment switching: Changing therapy that achieved partial response may lead to loss of response without recapture 4
- Ignoring patient-reported outcomes: The 2024 comprehensive disease control definition emphasizes urgency, abdominal pain, fatigue, and sleep disturbance—symptoms not captured in traditional remission definitions 3
Evidence Strength Caveat
The evidence supporting treat-to-target in ulcerative colitis is significantly more limited than in Crohn's disease 6. Most supporting data are retrospective, and prospective validation of STRIDE-II implementation in real-world practice remains incomplete 7, 8. Despite this limitation, the consensus-based framework provides the best available guidance for systematic disease management.